Lack of effect of mianserin on the symptoms of diabetic neuropathy.
The effect of the non-tricyclic antidepressant mianserin on symptoms of diabetic neuropathy has been studied in 18 patients in a double-blind, cross-over study with imipramine as a positive control. The patients were treated with placebo, mianserin, and imipramine, each for two weeks, in randomized order, with 1-3 weeks between the treatments. The symptoms were assessed by observer and self-rating scales. Mianserin was given in the fixed dosage of 60 mg per day, whereas the dose of imipramine was adjusted to yield the optimal plasma concentration of imipramine plus desipramine of 400-600 nmol.l-1. The mianserin plus desmethylmianserin plasma concentration ranged from 85 to 850 nmol.l-1, with the highest concentration in a patient who was a poor metabolizer of both sparteine and mephenytoin. The symptoms of neuropathy were significantly reduced during imipramine treatment, although somewhat less than in earlier studies. In contrast, mianserin produced no change in symptoms in comparison with placebo. As there was no evidence that higher mianserin (plus metabolite) steady-state concentrations were associated with a more favourable effect, the negative outcome appeared not to be related to underdosing with mianserin. In contrast to drugs with documented effects on the symptoms of diabetic neuropathy, mianserin has a very weak or no inhibitory effect on 5-HT and noradrenaline reuptake and this may explain its poor clinical effect.
Sindrup
S H
SH
Department of Clinical Pharmacology, Odense University, Denmark.
Tuxen
C
C
Gram
L F
LF
Grodum
E
E
Skjold
T
T
Brøsen
K
K
Beck-Nielsen
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000378:metabolism; D003891:Desipramine / Q000009:adverse effects / Q000627:therapeutic use; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged
D001786:Blood Glucose; D008803:Mianserin; D007099:Imipramine; D003891:Desipramine